Pliant Therapeutics releases longer-term safety, preliminary efficacy data from PhIIa study

Amber Tong

A new update on Pliant Therapeutics’ oral drug for idiopathic pulmonary fibrosis (IPF) suggests its safety and early signs of efficacy are holding up in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pliant Therapeutics releases longer-term safety, preliminary efficacy data from PhIIa study

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pli­ant Ther­a­peu­tics re­leas­es longer-term safe­ty, pre­lim­i­nary ef­fi­ca­cy da­ta from PhI­Ia study

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pliant Therapeutics releases longer-term safety, preliminary efficacy data from PhIIa study